Rodrigo Diaz M.

In a statement, Pfizer said it had completed the first phase of the study of the effects of its vaccine in children, which was designed to determine the optimal dose for children of different age groups.

The second and third phases of the study are currently underway, according to the company, “to further evaluate the safety, tolerability and immunogenicity of the Pfizer-BioNTech vaccine against COVID-19 in children ages 5 to 11 years, and in children from 6 months to 5 years ”.

“If safety and immunogenicity are confirmed, we plan to submit the data to Health Canada before the end of the year to support a possible authorization for children ages 5-11, and shortly thereafter for children ages 6 months to 5 years,” he wrote. the company.

This data should be reviewed by Health Canada to determine if the government will authorize the use of the Pfizer-BioNTech vaccine in children under 12 years of age. Health Canada approved the use of the vaccine in children ages 12 to 16 in May 2021.

Moderna, which makes a COVID-19 vaccine approved for use in people over 16 years of age, only said that its study of its vaccine in the population under 16 years is “in progress” and did not want to give details on a definitive schedule.

AstraZeneca said its partner, the University of Oxford, was also conducting studies in children of its COVID-19 vaccine.

“The trial continues without safety concerns and details of the immune responses will be provided when available,” the company said in a statement.

Trending on Canadian News  War in Ukraine: Moscow increases pressure in the east and south of the country | War in Ukraine

Leave a Reply

Your email address will not be published.